Cancer Clinical Trials

A Critical Appraisal

  • Hans Scheurlen
  • Richard Kay
  • Michael Baum
Conference proceedings

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 111)

Table of contents

  1. Front Matter
    Pages I-XI
  2. Scientific Fundamentals

  3. Heterogeneous Treatment Effects

  4. On Combining Information: Historical Controls, Overviews, and Comprehensive Cohort Studies

  5. Subjective Opinions and Informed Consent

  6. Assessment of Quality of Life

    1. N. K. Aaronson, M. Bullinger, S. Ahmedzai
      Pages 231-249
    2. M. Olschewski, R. Verres, H. Scheurlen, H. Rauschecker
      Pages 258-269
  7. Back Matter
    Pages 270-272

About these proceedings


The controlled clinical trial has become an essential part of the clinician's decision-making process. Clinical trials, however, still raise methodological problems that are important and at the same time controversial: subgroup analysis and interactions, meta-analy­ sis of similar trials, consideration of subjective clinical opinions and those of the public at large, assessment of quality of life, pre­ vention trials, and so on. In February 1987 we took our third step along the road to evaluating these issues in dialogues between cli­ nicians, psychologists, legal experts, and statisticians. The talks presented at the meeting were revised by the authors afterwards and have been rearranged by the editors to form a strictly organ­ 1 2 ized book. The two preceding meetings in 1978 and 1981 focused strongly on adjuvant therapy in primary breast cancer, but this top­ ic served merely as a nucleus in the third meeting. This meeting, although called the Third Heidelberg Symposium was forced to leave Heidelberg and in fact was held in Freiburg. Without the interest and enthusiasm of Professor Martin Schu­ macher and his colleagues in Freiburg the meeting would never have taken place. The meeting was generously supported again by the Federal Ministry of Research and Technology (Bundesministe­ rium flir Forschung und Technologie, BMFT) within the framework of the West German BMFT Breast Cancer Study Group. We are grateful, in particular, to Mr. Hans W. Herzog for his personal in­ volvement. Juni 1988 H. Scheurlen, R. Kay, M.


adjuvant therapy breast cancer cancer cancer prevention cancer treatment clinical trial morbidity prevention quality of life radiotherapy

Editors and affiliations

  • Hans Scheurlen
    • 1
  • Richard Kay
    • 2
  • Michael Baum
    • 3
  1. 1.Institut für Medizinische Biometrie und InformatikUniversität HeidelbergHeidelbergGermany
  2. 2.Department of Probability and StatisticsUniversity of SheffieldSheffieldGreat Britain
  3. 3.King’s College, School of Medicine and DentistryCRC Clinical Trials Centre, Rayne InstituteLondonGreat Britain

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1988
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-83421-9
  • Online ISBN 978-3-642-83419-6
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology